Work

Randomized open-label study of M7824 versus pembrolizumab as first-line (1L) treatment in patients with PD-L1 expressing advanced non-small cell lung cancer (NSCLC).

Year: 2019

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2019.37.8_suppl.tps127

Authors: Myung-Ju Ahn, Fabrice Barlesi, Enriqueta Felip, Edward B. Garon, Claudio Marcelo Martin, Tony S. K. Mok, Everett E. Vokes, Laureen S. Ojalvo, Andre Koenig, Isabelle Dussault, Luis G. Paz-Ares

Institutions: Samsung Medical Center, Aix-Marseille Université, Centre de Recherche en Cancérologie de Marseille, Vall d'Hebron Hospital Universitari, University of California, Los Angeles, Ronald Reagan UCLA Medical Center, Instituto Alexander Fleming, Chinese University of Hong Kong, University of Chicago, Merck Healthcare KGaA, Darmstadt (Germany), Merck KGaA, Darmstadt (Germany), Hospital Universitario 12 De Octubre

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4244786166

Cites:

Cited by: 2

Related to: 10